论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
堪萨斯分枝杆菌感染患者干扰素-γ 释放测定的性能
Authors Gao CH, Zhang YA, Wang MS
Received 9 August 2022
Accepted for publication 14 November 2022
Published 28 December 2022 Volume 2022:15 Pages 7727—7732
DOI https://doi.org/10.2147/IDR.S385570
Checked for plagiarism Yes
Review by Single anonymous peer review
Peer reviewer comments 2
Editor who approved publication: Professor Suresh Antony
Objective: To evaluate the performance of interferon-γ release assays (IGRAs) in patients with Mycobacterium kansasii infection.
Methods: Consecutive patients between May 2012 and June 2021 who had positive for mycobacterial cultures and who underwent IGRAs (T-SPOT.TB or QuantiFERON-TB Gold [QFT-G]) were included in the analysis. The IGRA positivity rates among patients with M. kansasii isolates were then calculated. If M. kansasii was identified in at least two sputum samples or in sterile samples, M. kansasii disease was then diagnosed. Otherwise, colonisation was considered.
Results: During the study period, 54 patients with M. kansasii infection underwent T-SPOT.TB (n=48) or QFT-G (n=6) assays. The mean age was 44.1± 13.4 years, 85.2% (46/54) were male. Eight patients were diagnosed with M. kansasii disease and another 46 patients were considered to have colonisation. Twenty-four patients (T-SPOT.TB, n=23; QFT-G, n=1) were positive for IGRAs, for an overall rate of 44.4% (24/54; T-SPOT.TB, 47.9% [23/48]; QFT-G, 16.7% [1/6]) for IGRAs, 25.0% (2/8) for M. kansasii disease, and 47.8% (22/46) for colonisation.
Conclusion: Positive IGRA rates were relatively low in patients with M. kansasii infection. More efforts are required to improve the performance of IGRAs in diagnosing M. kansasii infection.
Keywords: interferon-gamma release assay, tuberculosis, M. kansasii , diagnosis, infection